PROJECT SUMMARY
Arboviruses maintained in a human-mosquito-human transmission cycle are responsible for fueling periodic
outbreaks worldwide and are an increasing public health threat. A critical feature of arbovirus transmission cycles,
and a major determinant of their geographic spread and pathogenesis, is the magnitude and duration of viremia
in vertebrate hosts. However, few studies have investigated the molecular determinants of viremia. Recent
studies published by the Morrison laboratory demonstrated that the murine scavenger receptor MARCO on liver
macrophages removes chikungunya (CHIKV) particles and other arthritogenic alphaviruses, including Ross
River (RRV) and o’nyong ‘nyong (ONNV) viruses, from murine circulation due to recognition of the lysine (K)
residue at position 200 of CHIKV and ONNV E2 glycoprotein and 251 of RRV E2 glycoprotein. My preliminary
studies further revealed that CHIKV clearance is also abrogated when mutations were introduced at glutamate
(E)208 of E2 and K61 of E1 glycoproteins, and mass spectrometry analysis of the biochemical features important
for viral clearance suggested that E1 K61 is methylated. Further analysis of position 208 of CHIKV E2
glycoprotein revealed the importance of a negative charge at this position for CHIKV removal from circulation.
As a pattern recognition receptor, MARCO recognizes modified self and non-self molecules, and polymorphisms
in human MARCO can predispose carriers to infectious diseases such as tuberculosis. Because the scavenger
receptor cysteine-rich (SRCR) domain of MARCO is a binding site for endogenous ligands, such as modified
low-density lipoprotein, I hypothesize that the SRCR domain of MARCO stably and noncovalently interacts
with an exposed interface between the E1 and E2 glycoproteins of CHIKV, allowing for the removal of
viral particles from circulation and a reduction in both the magnitude and duration of viremia. In Aim 1,
I will define the residues and biochemical features of CHIKV important for MARCO-dependent clearance from
circulation by manipulating surface features of virus particles, assessing how specific mutations impact viral
dissemination, and identifying post-translational modifications at specific sites in the E1 and E2 glycoproteins. In
Aim 2, I will elucidate the sites on MARCO responsible for binding arthritogenic alphaviruses with cell-based and
biochemical approaches. In addition, I will determine the extent to which virus particles interact with human
MARCO, and whether known polymorphisms in MARCO affect virus-MARCO interactions, viremia, or clinical
outcomes. Taken together, by defining the molecular mechanism of interaction between MARCO and CHIKV,
this proposal could provide insights into factors that influence alphaviral pathogenesis, elucidate the relationship
between MARCO polymorphisms and viremia, and identify individuals or populations with an increased
susceptibility to severe alphaviral infections and outbreaks, respectively.